A Phase 2 proof-of-concept efficacy study for the treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD)
Latest Information Update: 20 May 2023
Price :
$35 *
At a glance
- Drugs PUR 1800 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- 12 May 2023 According to a Pulmatrix media release, the completed data analysis is expected to inform the study design of this study. company plans to pursue partnership opportunities to advance PUR1800 into a potential this Phase 2 clinical trial.
- 12 Apr 2021 According to a Pulmatrix media release, this study is not expected to commence until 2022.
- 19 Feb 2019 According to a Pulmatrix media release, the company expects to initiate CMC development work preparation for this study in 2019.